You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

mass. movers

Drug maker slides after trial disappoints

Merrimack’s drug testing targeted a type of  ovarian cancer.

istockphoto.com

Merrimack’s drug testing targeted a type of ovarian cancer.

Continue reading below

Merrimack Pharmaceuticals Inc., a Cambridge company focused on developing cancer therapies, fell after it reported results from a mid-stage study involving the drug MM-121 in combination with Paclitaxel to treat platinum-resistant or refractory-advanced ovarian cancer. MM-121, being developed with Sanofi, did not meet its primary “endpoint” of improving progression-free survival. There was no statistical difference between MM-121 with Paclitaxel and Paclitaxel alone. Side effects like diarrhea and vomiting were more prevalent in the group taking MM-121.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week